

big ten cancer research consortium

big ten cancer research consortium represents a groundbreaking collaboration among leading academic institutions dedicated to advancing cancer research across the United States. This consortium unites the expertise and resources of the Big Ten universities, aiming to accelerate the discovery of innovative cancer treatments, improve patient outcomes, and enhance clinical trial efficiency. By leveraging shared data, advanced technology, and multidisciplinary teams, the Big Ten Cancer Research Consortium fosters robust scientific inquiry and translational research. This article delves into the consortium's structure, key research initiatives, clinical trials, and its impact on cancer therapies. Readers will gain insight into how this collaboration is shaping the future of oncology research and patient care. The following sections provide a comprehensive overview of the Big Ten Cancer Research Consortium and its pivotal role in the fight against cancer.

- Overview of the Big Ten Cancer Research Consortium
- Research Focus Areas and Innovations
- Clinical Trials and Patient Impact
- Collaborative Infrastructure and Data Sharing
- Future Directions and Challenges

Overview of the Big Ten Cancer Research Consortium

The Big Ten Cancer Research Consortium is a consortium of major research universities primarily located in the Midwestern and Eastern United States. It is an alliance designed to pool academic expertise, clinical resources, and research infrastructure to enhance the study and treatment of various cancers. The consortium includes institutions renowned for their medical research capabilities and comprehensive cancer centers. By forming this unified network, the consortium aims to overcome traditional barriers in oncology research such as limited patient populations, fragmented data, and resource constraints.

Member Institutions

The consortium is composed of the cancer centers affiliated with the Big Ten universities, each contributing unique strengths in cancer biology, clinical oncology, and translational medicine. These institutions have a long-standing

history of cancer research and patient care, providing a solid foundation for collaborative efforts. Together, they represent a diverse population base and a wide range of cancer types, which enhances the generalizability and scope of research findings.

Mission and Goals

The primary mission of the Big Ten Cancer Research Consortium is to accelerate the development of novel cancer therapies through collaborative research and clinical trials. It seeks to improve survival rates and quality of life for cancer patients by fostering innovation, expanding access to clinical trials, and promoting data-driven decision-making. The consortium also prioritizes training the next generation of cancer researchers and clinicians, ensuring sustained advancements in the field.

Research Focus Areas and Innovations

The Big Ten Cancer Research Consortium emphasizes multidisciplinary research, integrating basic science, clinical studies, and population health. This approach facilitates comprehensive investigations into cancer mechanisms and therapeutic strategies. Key research areas include genomics, immunotherapy, targeted therapies, and cancer prevention.

Genomic and Molecular Research

One of the consortium's major research thrusts is the exploration of cancer genomics. By studying genetic mutations, epigenetic changes, and molecular pathways, researchers aim to identify biomarkers for early detection and develop personalized treatment options. This precision oncology approach tailors therapies based on individual tumor profiles, improving efficacy and minimizing adverse effects.

Immunotherapy Advances

Immunotherapy represents a transformative area within the Big Ten Cancer Research Consortium's projects. Investigators focus on harnessing the immune system to target and destroy cancer cells. This includes checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines. The consortium's collaborative structure enables rapid testing and optimization of these innovative treatments across multiple institutions.

Prevention and Epidemiology

In addition to therapeutic research, the consortium conducts extensive

studies on cancer prevention and epidemiology. Understanding risk factors, lifestyle influences, and environmental exposures contributes to comprehensive cancer control strategies. These efforts support public health initiatives aimed at reducing cancer incidence and promoting early diagnosis.

Clinical Trials and Patient Impact

The Big Ten Cancer Research Consortium is distinguished by its robust clinical trial network, which facilitates the enrollment of diverse patient populations into cutting-edge studies. This network accelerates the translation of laboratory discoveries into effective therapies and improves access to novel treatments for patients.

Trial Design and Implementation

The consortium employs innovative trial designs, including adaptive trials and biomarker-driven studies. These methodologies increase trial efficiency and relevance by allowing modifications based on interim results and patient-specific characteristics. This strategy ensures that clinical research remains responsive to evolving scientific insights.

Patient Enrollment and Diversity

Ensuring broad patient participation is a core priority. The consortium leverages its multi-institutional reach to enroll patients across different demographic and geographic backgrounds. This diversity enhances the validity of trial outcomes and promotes equity in access to experimental therapies.

Examples of Key Clinical Trials

- Immunotherapy trials targeting advanced lung and melanoma cancers
- Precision medicine studies focusing on genetic mutations in breast and colorectal cancers
- Prevention trials assessing novel chemopreventive agents in high-risk populations
- Combination therapy trials integrating targeted agents with standard chemotherapy

Collaborative Infrastructure and Data Sharing

Central to the Big Ten Cancer Research Consortium's success is its sophisticated infrastructure supporting collaboration and data sharing. This includes integrated biobanks, centralized data repositories, and standardized protocols that facilitate seamless cooperation among member institutions.

Data Integration Platforms

The consortium utilizes advanced informatics tools to aggregate and analyze clinical and molecular data from participating centers. Harmonized data management enables researchers to conduct large-scale analyses, identify patterns, and generate robust hypotheses, accelerating discovery.

Biobanking and Specimen Sharing

Access to high-quality biological specimens is critical for translational cancer research. The consortium's shared biobank system ensures standardized collection, storage, and distribution of tumor samples, blood, and other biospecimens. This resource supports studies ranging from molecular profiling to drug development.

Multidisciplinary Collaboration

The consortium fosters an environment of multidisciplinary collaboration by bringing together oncologists, pathologists, geneticists, bioinformaticians, and other experts. Regular meetings, workshops, and symposia facilitate knowledge exchange and promote innovative approaches to complex cancer challenges.

Future Directions and Challenges

Looking ahead, the Big Ten Cancer Research Consortium aims to expand its scientific scope and enhance the impact of its research on clinical practice. Embracing emerging technologies and addressing ongoing challenges remain priorities to sustain progress.

Integration of Artificial Intelligence and Machine Learning

The consortium is actively exploring the application of AI and machine learning to improve cancer diagnosis, predict treatment responses, and optimize clinical trial design. These technologies hold promise for uncovering novel insights from complex datasets and personalizing patient

care.

Addressing Disparities in Cancer Care

Despite advances, disparities in cancer outcomes persist across socioeconomic and racial groups. The consortium is committed to investigating these disparities and developing interventions to promote equitable access to prevention, diagnosis, and treatment services.

Expanding Collaborative Networks

Future plans include broadening partnerships beyond the Big Ten institutions to include community hospitals, international collaborators, and industry partners. Such expansion is expected to amplify resources, diversify research portfolios, and accelerate translation of discoveries into clinical benefits.

- Enhancing patient-centered research models
- Incorporating real-world evidence in clinical studies
- Strengthening training programs for oncology researchers

Frequently Asked Questions

What is the Big Ten Cancer Research Consortium?

The Big Ten Cancer Research Consortium is a collaborative network of cancer research centers affiliated with Big Ten universities, aimed at accelerating cancer research and improving patient outcomes through shared resources and expertise.

Which universities are part of the Big Ten Cancer Research Consortium?

The consortium includes cancer centers from Big Ten universities such as the University of Michigan, Ohio State University, University of Wisconsin, Penn State University, Northwestern University, and others within the Big Ten Conference.

What are the main goals of the Big Ten Cancer

Research Consortium?

The main goals are to facilitate multi-institutional clinical trials, promote collaborative research projects, share data and biospecimens, and advance precision oncology to improve cancer diagnosis and treatment.

How does the Big Ten Cancer Research Consortium benefit cancer patients?

By combining expertise and resources across leading research institutions, the consortium enables faster development of innovative therapies, access to cutting-edge clinical trials, and improved personalized treatment options for cancer patients.

Are there ongoing clinical trials within the Big Ten Cancer Research Consortium?

Yes, the consortium actively conducts multi-center clinical trials focusing on various cancer types, including lung, breast, prostate, and hematologic cancers, to evaluate new treatments and improve patient care outcomes.

Additional Resources

1. Advances in Big Ten Cancer Research: Collaborative Approaches and Innovations

This book explores the groundbreaking research emerging from the Big Ten Cancer Research Consortium, highlighting collaborative efforts between member institutions. It delves into innovative methodologies, clinical trials, and translational research that are shaping cancer treatment. Readers gain insight into how teamwork across universities accelerates discoveries and improves patient outcomes.

2. Precision Oncology in the Big Ten: Targeted Therapies and Personalized Medicine

Focusing on the role of precision medicine within the Big Ten Cancer Research Consortium, this volume discusses targeted therapies tailored to individual genetic profiles. It covers advances in biomarker identification, genomic sequencing, and the implementation of personalized treatment plans. The book underscores the consortium's impact on advancing precision oncology.

3. Big Ten Cancer Consortium: Bridging Research and Clinical Practice

This book provides an overview of how the Big Ten Cancer Consortium bridges the gap between laboratory research and clinical application. It includes case studies on successful translational research projects and outlines strategies for effective collaboration. Healthcare professionals and researchers will find valuable information on moving discoveries from bench to bedside.

4. *Innovations in Cancer Immunotherapy: Insights from the Big Ten Consortium*
Dedicated to recent progress in cancer immunotherapy, this book showcases studies and clinical trials conducted within the Big Ten Cancer Research Consortium. It highlights novel immune checkpoint inhibitors, vaccine development, and combination therapies. The text serves as a resource for understanding the evolving landscape of immuno-oncology.

5. *Data-Driven Cancer Research: Big Ten Consortium's Role in Bioinformatics and AI*

Exploring the integration of bioinformatics and artificial intelligence in cancer research, this book discusses how the Big Ten Cancer Research Consortium leverages big data to improve diagnosis and treatment. It covers machine learning models, data sharing platforms, and computational biology techniques. The book emphasizes the transformative power of data science in oncology.

6. *Clinical Trials and Patient Outcomes: Lessons from the Big Ten Cancer Research Consortium*

This volume reviews the design, execution, and results of clinical trials conducted by the Big Ten Cancer Research Consortium. It highlights patient recruitment strategies, ethical considerations, and outcome analysis. The book provides valuable insights into optimizing clinical research to enhance patient care.

7. *Collaborative Research Infrastructure: Building the Big Ten Cancer Consortium*

Focusing on the organizational and infrastructural aspects, this book details how the Big Ten Cancer Consortium was established and operates. It covers governance, funding models, data sharing agreements, and collaborative frameworks. The text is essential for institutions aiming to develop multi-center research networks.

8. *Emerging Therapies in Pediatric Oncology: Contributions from the Big Ten Research Network*

This book addresses the unique challenges and advancements in pediatric cancer research within the Big Ten Cancer Research Consortium. It discusses novel therapeutic approaches, clinical trial progress, and supportive care innovations for children with cancer. The consortium's role in improving pediatric oncology outcomes is thoroughly examined.

9. *Big Ten Cancer Research Consortium: A Decade of Impact and Future Directions*

Reflecting on ten years of collaborative cancer research, this volume summarizes key achievements and outlines future priorities for the Big Ten Cancer Research Consortium. It includes perspectives from leading scientists, clinicians, and patient advocates. The book serves as both a retrospective and a roadmap for continued progress in cancer research.

Big Ten Cancer Research Consortium

Find other PDF articles:

<http://www.devensbusiness.com/archive-library-402/files?trackid=mwN30-3360&title=i-love-utah-hi-story.pdf>

big ten cancer research consortium: The SAGE Encyclopedia of Cancer and Society

Graham A. Colditz, 2015-08-12 The first edition of the Encyclopedia of Cancer and Society was published in 2007 and received a 2008 Editors' Choice Award from Booklist. It served as a general, non-technical resource focusing on cancer from the perspective of the social and behavioral sciences, exploring social and economic impacts, the "business" of cancer, advertising of drugs and treatment centers, how behavior change could offer great potential for cancer prevention, environmental risks, food additives and regulation, the relation between race and ethnicity and cancer risk, socioeconomic status, controversies—both scientific and political—in cancer treatment and research, country-by-country entries on cancer around the world, and more. Given various developments in the field including new drug treatments, political controversies over use of the vaccines Gardasil and Cervarix with young girls to prevent cervical cancer, and unexpected upticks in the prevalence of adult smoking within the U.S. following decades of decline, the SAGE Encyclopedia of Cancer and Society, Second Edition serves as an updated and more current encyclopedia that addresses concerns pertaining to this topic. Key Features: · Approximately half of the 700 first-edition articles revised and updated · 30+ new entries covering new developments since 2006 · Signed entries with cross-references · Further Readings accompanied by pedagogical elements · New Reader's Guide · Updated Chronology, Resource Guide, Glossary, and through new Index The SAGE Encyclopedia of Cancer and Society, Second Edition serves as a reliable and precise source for students and researchers with an interest in social and behavioral sciences and seeks to better understand the continuously evolving subject matter of cancer and society.

big ten cancer research consortium: Frontiers in Anti-Cancer Drug Discovery

Atta-ur-Rahman, M. Iqbal Choudhary, 2018-12-06 Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The ninth volume of the series features chapters covering the following topics: - New research on the therapeutic intervention of cancer and cancer drug delivery - Dabrafenib usage in melanoma therapy - Targeting autophagy in cancer therapy - Pro-apoptotic and anti-telomerase activity of naturally occurring compounds - CDK inhibitors - Oral nanostructure drug delivery for anti-cancer treatment

big ten cancer research consortium: Cancer Treatment Nima Rezaei, 2025-10-07 The rapid flow of studies in the field of cancer and immunology during the last decades has increased our understanding of the interactions between the immune system and cancerous cells. In particular, it has been well-known that such interactions result in the induction of epigenetic changes in cancerous cells and the selection of less immunogenic clones as well as alterations in immune responses. Understanding the crosstalk between nascent transformed cells and cells of the immune system has led to the development of combinatorial immunotherapeutic strategies to combat cancer. The Handbook of Cancer and Immunology offers a comprehensive and up-to-date review of cancer

immunology and immunotherapy, emphasizing key findings and clinically relevant data. This reference work is an essential resource for researchers, students, academics, and clinicians committed to advancing knowledge, diagnostics, and treatments in this vital field.

big ten cancer research consortium: Novel Molecular Targets and Treatments for Gastroesophageal Cancer Bin Li, Alfred King-yin Lam, Linhui Liang, Jianjun Xie , Wen Wen Xu, 2024-09-25 Gastroesophageal cancer is among the most common malignant diseases worldwide and is associated with high mortality rates, leading to a substantial burden on public health and healthcare systems around the world. Chemotherapeutic drugs have achieved great success in the treatment of esophageal cancer; however, they also bring cytotoxicity to other organs and often have serious side effects. With the development of molecular diagnostics and biomarker discovery, the application of precision medicine has emerged to improve clinical outcomes.

big ten cancer research consortium: Renal Cell Carcinoma José I. López, 2020-04-22 Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70-80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe-oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.

big ten cancer research consortium: How to Select Patients With Thoracic Cancers for Immunotherapy-Chemotherapy or Immunotherapy-Angiogenesis Inhibitor Combinations? Weimin Mao, Herbert Yu, Qibin Song, Kai Wang, 2022-11-28

big ten cancer research consortium: Oxford Textbook of Urological Surgery Freddie C. Hamdy, Ian Eardley, 2017-10-20 Offering a comprehensive guide, the Oxford Textbook of Urological Surgery is a practical resource mapped to the curriculum for urological training as approved by the General Medical Council (GMC), making it particularly useful in preparation for the Intercollegiate Examination. Presented in a clear and accessible way, this evidence based volume covers all major areas, including functional urology, stone disease, infection, andrology, nephrology, transplantation, uroradiology, and paediatric urology. This highly illustrated full colour textbook has an innovative and user-friendly style, including over 500 photographs, clinical images, and line drawings. Bringing together the expertise of over 100 specialist contributors in the field, the Oxford Textbook of Urological Surgery is a highly valuable source of information, and will become the standard reference text for all who study urological disease and its treatment.

big ten cancer research consortium: Community series in combining chemo/radio therapy and immunotherapy for cancers— perfect mix of old and new, volume II Jian Zhang, Linlang Guo, Feng-Ming (Spring) Kong, Clare Y. Slaney, 2023-08-23

big ten cancer research consortium: A year in review: Discussions in cancer immunity and immunotherapy Catherine Sautes-Fridman, Katy Rezvani, 2023-06-07

big ten cancer research consortium: The President's Report to the Board of Regents for the Academic Year ... Financial Statement for the Fiscal Year University of Michigan, 1977

big ten cancer research consortium: Penn State President's Report, 1990-1992 Joab Thomas, 1993*

big ten cancer research consortium: National Directory of Nonprofit Organizations , 2002

big ten cancer research consortium: IU Newspaper , 1991

big ten cancer research consortium: Evaluating Research Centers and Institutes for Success!
William R. Tash, 2006

big ten cancer research consortium: Cumulated Index Medicus , 1999

big ten cancer research consortium: Pediatric Hypertension Joseph T. Flynn, Julie R. Ingelfinger, Tammy M. Brady, 2023-01-09 For the past 17 years, Pediatric Hypertension has served as the definitive reference text on hypertension in children and adolescents. Each edition has incorporated the latest research on the pathophysiology, clinical significance and management of hypertension in the young, and has incorporated the most current consensus guidelines on diagnosis and management. The years since publication of the fourth edition have seen further advances in the field that merit publication of an updated, expanded text, including: Analysis of the implications of updated hypertension guidelines on identification of youth at highest cardiovascular risk Additional data on the proximate effects of high blood pressure in children in adolescents Further understanding of the links between high blood pressure in youth and surrogate markers of adult cardiovascular disease The fifth edition is a readable, informative text that provides a comprehensive guide to the diagnosis, management and therapy of hypertension in children and adolescents, and presents new data that very clearly indicate that the origins of adult cardiovascular disease are rooted in pediatric hypertension. It will, as a result, be very important for therapeutic decisions and will also be highly relevant for those in internal medicine, who care for the millions of adults who have hypertension, cardiovascular disease and kidney disease. In this sense, the book fulfills the longstanding goal of showing that hypertension that begins in childhood is important to track, diagnose and treat, and that the present understanding of adult hypertension necessitates the study of blood pressure in youth. The fifth edition has a similar structural format to the prior editions and covers all aspects of pediatric hypertension, from basic science research to the most recent clinical information.

big ten cancer research consortium: **Dr. Susan Love's Breast Book** Susan M. Love, 2023-11-07 The Bible (New York Times) and the seminal work (LA Times) offering the most authoritative guidance through all stages of breast cancer diagnosis and recovery, fully revised and updated. While the amount of information regarding a breast cancer diagnosis is vaster than ever, online and off, what continues to be missing is the explanation behind the options. Most of the data online on medical sites is generic and often comes from the same source. Then there are the patient sites as well as many social media outlets that provide peer to peer support and information. This is important for emotional support but still leaves out the full range of options and the reasons for them. The Breast Book is where people go for a deeper understanding of how to make the best possible choices for their particular situations. Now in its seventh edition, the Breast Book has been fully revised to incorporate all the most recent developments in prevention, treatments and research. This new edition covers: New treatments: including new drugs, vaccines, hormonal treatment and drugs with longer duration (10 years) for the estrogen positive tumors The increasing focus on where cells live, both locally (immune system, hormones, etc.) and systemically (stress, etc.) Prevention: several new drugs have been added to the list of chemoprevention drugs. In addition, preventative surgery has received increased attention. Increased data on alternative approaches such as stress reduction and exercise in reducing recurrence. Increased understanding of the immune system and how it either controls or promotes the cancer. Risks for survivors Genetics Special groups: Men with breast cancer are demanding a louder voice in the conversation and research.

big ten cancer research consortium: *Cumulative List of Organizations Described in Section 170 (c) of the Internal Revenue Code of 1954* United States. Internal Revenue Service, 1998

big ten cancer research consortium: Cumulative List of Organizations Described in Section 170 (c) of the Internal Revenue Code of 1986 , 1988

big ten cancer research consortium: *Congressional Record* United States. Congress, 1975

Related to big ten cancer research consortium

BIG | Bjarke Ingels Group BIG has grown organically over the last two decades from a founder, to a family, to a force of 700. Our latest transformation is the BIG LEAP: Bjarke Ingels Group of Landscape, Engineering,

Hungarian Natural History Museum | BIG | Bjarke Ingels Group Our latest transformation is the BIG LEAP: Bjarke Ingels Group of Landscape, Engineering, Architecture, Planning and Products. A plethora of in-house perspectives allows us to see

Superkilen | BIG | Bjarke Ingels Group The park started construction in 2009 and opened to the public in June 2012. A result of the collaboration between BIG + Berlin-based landscape architect firm TOPOTEK 1 and the

Yongsan Hashtag Tower | BIG | Bjarke Ingels Group BIG's design ensures that the tower apartments have optimal conditions towards sun and views. The bar units are given value through their spectacular views and direct access to the

Manresa Wilds | BIG | Bjarke Ingels Group BIG has grown organically over the last two decades from a founder, to a family, to a force of 700. Our latest transformation is the BIG LEAP: Bjarke Ingels Group of Landscape, Engineering,

Serpentine Pavilion | BIG | Bjarke Ingels Group When invited to design the 2016 Serpentine Pavilion, BIG decided to work with one of the most basic elements of architecture: the brick wall. Rather than clay bricks or stone blocks - the wall

301 Moved Permanently 301 Moved Permanently301 Moved Permanently cloudflare
big.dk

The Twist | BIG | Bjarke Ingels Group After a careful study of the site, BIG proposed a raw and simple sculptural building across the Randselva river to tie the area together and create a natural circulation for a continuous art

VIA 57 West | BIG | Bjarke Ingels Group BIG essentially proposed a courtyard building that is on the architectural scale - what Central Park is at the urban scale - an oasis in the heart of the city

BIG | Bjarke Ingels Group BIG has grown organically over the last two decades from a founder, to a family, to a force of 700. Our latest transformation is the BIG LEAP: Bjarke Ingels Group of Landscape, Engineering,

Hungarian Natural History Museum | BIG | Bjarke Ingels Group Our latest transformation is the BIG LEAP: Bjarke Ingels Group of Landscape, Engineering, Architecture, Planning and Products. A plethora of in-house perspectives allows us to see what

Superkilen | BIG | Bjarke Ingels Group The park started construction in 2009 and opened to the public in June 2012. A result of the collaboration between BIG + Berlin-based landscape architect firm TOPOTEK 1 and the

Yongsan Hashtag Tower | BIG | Bjarke Ingels Group BIG's design ensures that the tower apartments have optimal conditions towards sun and views. The bar units are given value through their spectacular views and direct access to the

Manresa Wilds | BIG | Bjarke Ingels Group BIG has grown organically over the last two decades from a founder, to a family, to a force of 700. Our latest transformation is the BIG LEAP: Bjarke Ingels Group of Landscape, Engineering,

Serpentine Pavilion | BIG | Bjarke Ingels Group When invited to design the 2016 Serpentine Pavilion, BIG decided to work with one of the most basic elements of architecture: the brick wall. Rather than clay bricks or stone blocks - the wall

301 Moved Permanently 301 Moved Permanently301 Moved Permanently cloudflare
big.dk

The Twist | BIG | Bjarke Ingels Group After a careful study of the site, BIG proposed a raw and simple sculptural building across the Randselva river to tie the area together and create a natural circulation for a continuous art tour

VIA 57 West | BIG | Bjarke Ingels Group BIG essentially proposed a courtyard building that is on

the architectural scale - what Central Park is at the urban scale - an oasis in the heart of the city

Related to big ten cancer research consortium

'The rug has been pulled out from under us': Cancer research funding turmoil leaves families scrambling (26d) For two years, 5-year-old Juliette Lesko has battled an incurable form of brain cancer, ependymoma. After enduring two brain surgeries, 30 sessions of radiation, and two relapses, she is now being

'The rug has been pulled out from under us': Cancer research funding turmoil leaves families scrambling (26d) For two years, 5-year-old Juliette Lesko has battled an incurable form of brain cancer, ependymoma. After enduring two brain surgeries, 30 sessions of radiation, and two relapses, she is now being

Back to Home: <http://www.devensbusiness.com>